COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab

被引：29
|
作者：
Ungar, Benjamin [1 ,2 ]
Glickman, Jacob W. [1 ,2 ]
Golant, Alexandra K. [1 ,2 ]
Dubin, Celina [1 ,2 ]
Marushchak, Olga [1 ,2 ,3 ]
Gontzes, Alyssa [1 ,2 ]
Mikhaylov, Daniela [1 ,2 ]
Singer, Giselle K. [1 ,2 ]
Baum, Danielle [1 ,2 ]
Wei, Nancy [1 ,2 ]
Sanin, Antonio [1 ,2 ]
Gruenstein, Diana [1 ,2 ]
Lebwohl, Mark G. [1 ,2 ]
Pavel, Ana B. [1 ,2 ,3 ,4 ]
Guttman-Yassky, Emma [1 ,2 ]
机构：
[1] Icahn Sch Med Mt Sinai, Dept Dermatol, 5 E 98th St, New York, NY 10029 USA
[2] Icahn Sch Med Mt Sinai, Lab Inflammatory Skin Dis, 5 E 98th St, New York, NY 10029 USA
[3] Touro Coll Osteopath Med, New York, NY USA
[4] Univ Mississippi, Dept Biomed Engn, University, MS 38677 USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE | 2022年 / 10卷 / 01期
关键词：
Abbreviations used; ASTHMA; RISK; SKIN;
D O I：
10.1016/j.jaip.2021.10.050
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
BACKGROUND: In the SARS-CoV-2/COVID-19 pandemic, we need to understand the impact of immunomodulatory medications on COVID-19 symptom severity in patients with inflammatory diseases, including the type 2/Th2 polarized skin disease, atopic dermatitis (AD). OBJECTIVE: Because it is believed that type 1/Th1 immunity controls viral infections and that there is a Th1/Th2 counterregulation, we hypothesized that Th2 targeting with the IL4Ra-antagonist, dupilumab, in patients with moderate-to-severe AD would rebalance the Th1/Th2 axis, potentially leading to attenuated COVID-19 symptoms. METHODS: A total of 1237 patients with moderate-to-severe AD in the Icahn School of Medicine at Mount Sinai Department of Dermatology were enrolled in a registry. Patients were screened for COVID-19-related symptoms and assigned a severity score (asymptomatic [0]-fatal [5]). Scores were compared among 3 treatment groups: dupilumab (n = 632), other systemic treatments (n = 107), and limited/no treatment
引用
收藏
页码：134 / 142
页数：9
相关论文
共 50 条
  • [1] The psychological burden during COVID-19 pandemic in a cohort of patients affected by moderate-to-severe atopic dermatitis treated with dupilumab
    Quattrini, Laura
    Chiricozzi, Andrea
    Gori, Niccolo
    Di Nardo, Lucia
    D'Urso, Dario F.
    Malvaso, Dalma
    Cornacchia, Luigi
    Pano, Silvia Cata
    Peris, Ketty
    [J]. ITALIAN JOURNAL OF DERMATOLOGY AND VENEREOLOGY, 2023, 158 (04) : 365 - 367
  • [2] Dupilumab-associated hypereosinophilia in patients treated for moderate-to-severe atopic dermatitis
    Marcant, P.
    Balaye, P.
    Merhi, R.
    Jendoubi, F.
    Nosbaum, A.
    Raison-Peyron, N.
    Du-Thanh, A.
    Lasek, A.
    Ferrier le Bouedec, M. -C.
    Tetart, F.
    Valois, A.
    Barbarot, S.
    Soria, A.
    Jachiet, M.
    Staumont-Salle, D.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (06) : E394 - E396
  • [3] Clinically meaningful responses in moderate-to-severe atopic dermatitis patients treated with Dupilumab
    de Bruin-Weller, M.
    Eckert, L.
    Simpson, E. L.
    Cork, M. J.
    Ardeleanu, M.
    Chen, Z.
    Shumel, B.
    Rossi, A. B.
    Graham, N. M. H.
    Pirozzi, G.
    Gadkari, A.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 116 - 116
  • [4] COVID-19 Does Not Influence the Time to Relapse Following Dupilumab Discontinuation in Patients With Moderate-to-Severe Atopic Dermatitis
    Sun, Xiu-Kun
    [J]. DERMATITIS, 2024, 35 (05) : 523 - 524
  • [5] Dupilumab in the treatment of moderate-to-severe atopic dermatitis
    Kraft, Magdalena
    Worm, Margitta
    [J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2017, 13 (04) : 301 - 310
  • [6] Dupilumab: A Review in Moderate-to-Severe Atopic Dermatitis
    Frampton, James E.
    Blair, Hannah A.
    [J]. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2018, 19 (04) : 617 - 624
  • [7] Dupilumab: A Review in Moderate-to-Severe Atopic Dermatitis
    James E. Frampton
    Hannah A. Blair
    [J]. American Journal of Clinical Dermatology, 2018, 19 : 617 - 624
  • [8] Biomarkers in tear fluid of dupilumab-treated moderate-to-severe atopic dermatitis patients
    Achten, Roselie
    Thijs, Judith
    van Luijk, Chantal
    Knol, Edward
    Delemarre, Eveline
    de Graaf, Marlies
    Bakker, Daphne
    de Boer, Joke
    van Wijk, Femke
    de Bruin-Weller, Marjolein
    [J]. CLINICAL AND EXPERIMENTAL ALLERGY, 2023, 53 (02): : 239 - 243
  • [9] Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
    Beck, Lisa A.
    Thaci, Diamant
    Hamilton, Jennifer D.
    Graham, Neil M.
    Bieber, Thomas
    Rocklin, Ross
    Ming, Jeffrey E.
    Ren, Haobo
    Kao, Richard
    Simpson, Eric
    Ardeleanu, Marius
    Weinstein, Steven P.
    Pirozzi, Gianluca
    Guttman-Yassky, Emma
    Suarez-Farinas, Mayte
    Hager, Melissa D.
    Stahl, Neil
    Yancopoulos, George D.
    Radin, Allen R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (02): : 130 - 139
  • [10] Efficacy and tolerance of dupilumab in patients with moderate-to-severe atopic dermatitis and obesity
    Dupuis, Josephine
    Tauber, Marie
    Mahe, Emmanuel
    Jachiet, Marie
    Soria, Angele
    Tetart, Florence
    Puzenat, Eve
    Pasteur, Justine
    Raison-Peyron, Nadia
    Giordano-Labadie, Francoise
    Droitcourt, Catherine
    Leleu, Camille
    Nosbaum, Audrey
    Aubert, Helene
    Moigne, Marie L. E.
    Bernier, Claire
    Barbarot, Sebastien
    Ezzedine, Khaled
    Diaz, Emmanuelle
    Hubiche, Thomas
    Faiz, Sarah
    Azib, Selma
    Dezoteux, Frederic
    Chosidow, Olivier
    Staumont-Salle, Delphine
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2024,
12345